Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

A generic formulation of elexacaftor-tezacaftor-ivacaftor shows real-world benefits and appears safe in children and ...

Delve into bronchiectasis, a field long focused on managing symptoms that now has its first targeted treatment with ...

Susie Rider has raised $700K for cystic fibrosis research since her daughter was diagnosed with the disease 25 years ago.

Patients with cystic fibrosis often reduce or discontinue respiratory cotherapies after starting CFTR modulators without affecting clinical status.

The Emirates Drug Establishment (EDE) has granted regulatory approval for Jascayd (nerandomilast), which is prescribed for ...

The research group led by CIC biomaGUNE's Ikerbasque Research Professor Aitziber L. Cortajarena has developed an innovative ...

Background Fibrosis and tumour innervation are two features of the tumour microenvironment (TME) that contribute directly to ...

Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse ...

Cystic fibrosis causes thick, sticky mucus to build up in the lungs and digestive system, leading to severe respiratory and digestive complications. Without effective treatment, the disease can ...

HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech, today announced positive results from HistoIndex's AI-based quantitative analysis of liver ...